VTP-300 immunotherapeutic, plus low dose PD-1 inhibitor, nivolumab, continues to show meaningful, sustained reductions in HBsAg levels

Category Primary study
JournalJ. Hepatol.
Year 2024
This article has no abstract
Epistemonikos ID: d1d2ee362bcc29132535579adb2c7d7fbec06db7
First added on: Aug 26, 2025